"125I Labeled 3-iodobenzylguanidine" refers to a radiopharmaceutical compound that consists of 3-iodobenzylguanidine (IBG) molecule labeled with radioactive iodine-125 (125I). IBG is a chemical compound used in nuclear medicine as a diagnostic imaging agent for the detection and evaluation of certain types of tumors, particularly neuroblastoma and pheochromocytoma. The addition of the iodine-125 isotope to the compound allows for its detection using gamma imaging or scintigraphy.
The iodine-125 isotope used for labeling is a radioactive isotope of iodine, emitting gamma radiation which can be detected by specialized imaging equipment. This allows healthcare professionals to get a detailed view of the distribution and concentration of IBG within tissues and organs, aiding in the accurate diagnosis and staging of tumors.
The compound is administered to the patient intravenously, where it circulates through the bloodstream and binds to specific receptors found on tumor cells. The gamma radiation emitted by the radioactive iodine allows the imaging equipment to detect and create images of the tumor site.
Overall, 125I Labeled 3-iodobenzylguanidine serves as a valuable tool for physicians in the field of nuclear medicine, enabling them to non-invasively visualize and evaluate tumors with high precision. This aids in the planning of appropriate treatment strategies and monitoring the response to therapy.